Cargando…

Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer

Detalles Bibliográficos
Autores principales:	Dai, Lei-Jie, Li, Yu-Wei, Ma, Ding, Shao, Zhi-Ming, Jiang, Yi-Zhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618949/ https://www.ncbi.nlm.nih.gov/pubmed/37823691 http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0286

Ejemplares similares

Next Generation Sequencing Revolutionizes Organismal Biology Research in Bats
por: Garg, Kritika M., et al.
Publicado: (2023)

Revolutionizing cancer care with next-generation sequencing: an interview with Elaine Mardis
Publicado: (2014)

Precision medicine revolutionizes cancer diagnosis and treatment
por: Han, Chuanhui, et al.
Publicado: (2023)

Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
por: Zhuang, Weiliang, et al.
Publicado: (2023)

Revolutionizing Precision Medicine: Exploring Wearable Sensors for Therapeutic Drug Monitoring and Personalized Therapy
por: Liu, Yuqiao, et al.
Publicado: (2023)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Revolutionizing antiviral therapy with nanobodies: Generation and prospects
por: Mustafa, Mujahed I., et al.
Publicado: (2023)

Python deep learning: next generation techniques to revolutionize computer vision, AI, speech and data analysis
por: Zocca, Valentino, et al.
Publicado: (2017)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
por: Najjar, Mariana K., et al.
Publicado: (2022)

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
por: Escrivá-de-Romaní, Santiago, et al.
Publicado: (2023)

Imaging mass spectrometry for the precise design of antibody-drug conjugates
por: Fujiwara, Yuki, et al.
Publicado: (2016)

Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells
por: Chiang, Zu-Chian, et al.
Publicado: (2020)

Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging
por: Schumacher, Felix F., et al.
Publicado: (2014)

Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
por: Hartley-Brown, Monique, et al.
Publicado: (2022)

The power of phages: revolutionizing cancer treatment
por: Islam, Md. Sharifull, et al.
Publicado: (2023)

Revolutionizing semen analysis: introducing Mojo AISA, the next-gen artificial intelligence microscopy
por: Sengupta, Pallav, et al.
Publicado: (2023)

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
por: Chen, Yu‐Fei, et al.
Publicado: (2022)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
por: Albarrán, Víctor, et al.
Publicado: (2022)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody–Drug Conjugates
por: Feuillâtre, Ofelia, et al.
Publicado: (2020)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

Forming next-generation antibody–nanoparticle conjugates through the oriented installation of non-engineered antibody fragments
por: Greene, Michelle K., et al.
Publicado: (2017)

Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
por: Siddiqui, Tasmiyah, et al.
Publicado: (2022)

Plasma Robot Engineering: The Next Generation of Precision Disease Management
por: Dai, Xiaofeng, et al.
Publicado: (2021)

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

Genome editing is revolutionizing biology
por: Qi, Yiping
Publicado: (2017)

Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
por: Yu, Minghui, et al.
Publicado: (2023)

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia
por: Rainone, Michael, et al.
Publicado: (2023)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
por: Kim, Hyun Jung, et al.
Publicado: (2020)

JSKN003, A NOVEL BIPARATOPIC ANTI-HER2 ANTIBODY-DRUG CONJUGATE, EXHIBITS POTENT ANTITUMOR EFFICACY
por: Wang, Pilin, et al.
Publicado: (2023)

Revolutionizing Therapeutic Drug Monitoring with the Use of Interstitial Fluid and Microneedles Technology
por: Kiang, Tony K.L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9arsj7bdj04gghd4tv66ukpdg8